Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Affiliated Hangzhou Dermatology Hospital, Zhejiang University School of Medicine, Hangzhou, China.
School of Medicine, Zhejiang University, Yuhangtang, Hangzhou, China.
Front Immunol. 2023 May 2;14:1111547. doi: 10.3389/fimmu.2023.1111547. eCollection 2023.
Cytotoxic T lymphocyte has been a concern for the etiopathogenesis of alopecia areata (AA), some recent evidence suggests that the regulatory T (T) cell deficiency is also a contributing factor. In the lesional scalp of AA, T cells residing in the follicles are impaired, leading to dysregulated local immunity and hair follicle (HF) regeneration disorders. New strategies are emerging to modulate T cells' number and function for autoimmune diseases. There is much interest to boost T cells in AA patients to suppress the abnormal autoimmunity of HF and stimulate hair regeneration. With few satisfactory therapeutic regimens available for AA, T cell-based therapies could be the way forward. Specifically, CAR-T cells and novel formulations of low-dose IL-2 are the alternatives.
细胞毒性 T 淋巴细胞一直是斑秃（AA）发病机制的关注点，一些最新证据表明调节性 T（T）细胞缺乏也是一个促成因素。在 AA 的皮损头皮中，存在于毛囊中的 T 细胞受损，导致局部免疫失调和毛囊（HF）再生障碍。新的策略正在涌现，以调节 T 细胞的数量和功能，用于治疗自身免疫性疾病。人们对在 AA 患者中增加 T 细胞以抑制 HF 的异常自身免疫和刺激毛发生长非常感兴趣。由于 AA 可用的治疗方案很少，基于 T 细胞的治疗可能是未来的方向。具体来说，嵌合抗原受体 T 细胞（CAR-T 细胞）和低剂量白细胞介素 2（IL-2）的新制剂是替代方案。
